Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125560501 | 12556050 | 1 | I | 20160708 | 20160714 | 20160714 | EXP | CN-MYLANLABS-2016M1029126 | MYLAN | YANG S, LI S-Y, YU H, LI S, LIU W, LIU X, ET AL. METRONOMIC CHEMOTHERAPY WITH 5-FLUOROURACIL AND CISPLATIN FOR INOPERABLE MALIGNANT BOWEL OBSTRUCTION BECAUSE OF PERITONEAL DISSEMINATION FROM GASTRIC CANCER. CURR-ONCOL 2016;23(3):E248-E252. | 0.00 | Y | 0.00000 | 20160714 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125560501 | 12556050 | 1 | PS | FLUOROURACIL. | FLUOROURACIL | 1 | Intravenous drip | 300 MG/M2 DAILY ON DAY 1-5 AND DAY 8-12 EVERY 21 DAYS | U | 202668 | INJECTION | ||||||||
| 125560501 | 12556050 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous drip | 5 MG/M2 DAILY ON DAY 1-4 AND DAY 8-12 EVERY 21 DAYS | U | 0 | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125560501 | 12556050 | 1 | Chemotherapy |
| 125560501 | 12556050 | 2 | Chemotherapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125560501 | 12556050 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125560501 | 12556050 | Mucosal inflammation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |